Vitiligo [vitiligo]

dc.creatorSteiner D.
dc.creatorTadeu Villas R.
dc.creatorBedin V.
dc.creatorSteiner T.
dc.creatorBrito Moraes M.
dc.date2004
dc.date2015-06-26T14:23:58Z
dc.date2015-11-26T14:12:46Z
dc.date2015-06-26T14:23:58Z
dc.date2015-11-26T14:12:46Z
dc.date.accessioned2018-03-28T21:13:28Z
dc.date.available2018-03-28T21:13:28Z
dc.identifier
dc.identifierAnais Brasileiros De Dermatologia. , v. 79, n. 3, p. 335 - 351, 2004.
dc.identifier3650596
dc.identifier
dc.identifierhttp://www.scopus.com/inward/record.url?eid=2-s2.0-3242691612&partnerID=40&md5=b1f9914f7b2528b52610ed42cf09cd63
dc.identifierhttp://www.repositorio.unicamp.br/handle/REPOSIP/94311
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/94311
dc.identifier2-s2.0-3242691612
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1242099
dc.descriptionVitiligo is a skin disease of unknown etiology that affects 1% of the population. It affects both sexes equally and the mean age at onset is between 10 and 30 years. Some of the factors involved are: emotional or physical stress, mechanical trauma, chemicals such as phenol and certain diseases. Autoimmune diseases, especially of thyroid origin, may be linked to vitiligo. New and emerging therapies have been proposed such as topical immunomodulators, allied to traditional therapies with psoralen and steroids. The most important factor in the therapeutic success depends on the doctor and patient relationship.
dc.description79
dc.description3
dc.description335
dc.description351
dc.descriptionLerner, A.B., Nordlund, J.J., Vitiligo: What is it? Is it important? (1978) J Am Med Assoc, 239, pp. 1183-1187
dc.descriptionNordlund, J.J., Majumder, P.P., Recent investigations on vitiligo vulgaris: Advances in clinical research (1997) Dermatol Clin, 15, pp. 69-78
dc.descriptionEl-Mofty, A.M., (1968) Vitiligo and Psoralens, , Pergamon Press: New York
dc.descriptionNath, S.K., Majumder, P.P., Nordlund, J.J., Genetic epidemiology of vitiligo: Multilocus recessivity cross-validated (1994) Am J Hum Genetic, 55, pp. 981-990
dc.descriptionNodlund, J.J., Hypopigmentation, vitiligo and melanoma: New data, more enigmas (1998) Arch Dermatol, 123, pp. 1005-1011
dc.descriptionFoley, N.R., Lowe, N.J., Misheloff, E., Tiwari, J.L., Association of HLA-DR4 with vitiligo (1983) J Am Acad Dermatol, 8, pp. 39-40
dc.descriptionBehl, P.N., Bhatia, R.K., Treatment of vitiligo with autologous thin Thiersch's grafts (1973) Int J Dermatol, 12, pp. 329-331
dc.descriptionSlominski, A., Paul, R., Bomriski, A., Hypothesis: Possible role of melatonin receptors in vitiligo (1989) J R Soc Med, 82, pp. 539-541
dc.descriptionBarona, M.I., An epidemiological case-control study in a population with vitiligo (1995) J Am Acad Dermatol, 33 (4), pp. 621-625
dc.descriptionAbdel-Nasser, M.B., Further evidence for involvement of both cell mediated and humoral immunity in generalized vitiligo (1994) Pigment Cell Research, 7, pp. 1-8
dc.descriptionPorter, J., Beuf, A.H., Lerner, A.B., Nodlund, J.J., Response to cosmetic disfigurement
dc.descriptionpatients with vitiligo (1987) Cutis, 39, pp. 493-494
dc.descriptionNath, S.K., Manjumder, P.P., Nordlund, J.J., Genetic epidemiology of vitiligo: Multilocus recessivity cross-validated (1994) Am J Hum Genet, 55, pp. 981-990
dc.descriptionMajumder, P.P., Nordlund, J.J., Li, C.C., Pattern of familial aggregation of vitiligo (1993) Arch Dermatol, 129, pp. 994-998
dc.descriptionChen, I.T., Jimbow, K., Comparison in expression of tyrosinase, TRP-1, and c-Kit between normal human melanocytes and "vitiligo"melanocytes (1994) Pigment Cell Research, 24 (SUPPL. 3)
dc.descriptionNorris, D.A., Kissinger, R.M., Naughton, G.M., Evidence for immunologic mechanisms in human vitiligo: Patients' sera induce damage to human melanocytes in vitro by complement-mediated damage and antibody-dependent cellular toxicity (1998) J Invest Dermatol, 90, pp. 783-789
dc.descriptionOrtonne, J.P., Bose, S.K., Vitiligo: Where do we stand? Pigment Cell Research, 6, pp. 61-72
dc.descriptionBystryn, J.C., Immune mechanisms in vitiligo (1993) Clin Dermatol, 15, pp. 853-861
dc.descriptionBystryn, J.C., Naughton, G.K., The significance of vitiligo antibodies (1985) J Dermatol, 12, pp. 1-9
dc.descriptionZamani, M., Linkage and association of HLA class II genes with vitiligo in a Dutch population (2001) Br J Dermatol, 145, pp. 90-94
dc.descriptionBystryn, J.C., Xie, Z., Neoplastic hypomelanoses The Pigmentary System: Physiology and Pathophysiology, pp. 647-662. , Nordlund JJ, Boissy RE, Hearing VJ, King RA, eds. New York: Oxford University Press
dc.descriptionHarning, R., Cui, J., Bystryn, J.-C., Relation between the incidence and level of pigment cell antibodies and disease activity in vitiligo (1991) J Invest Dermatol, 97, pp. 1078-1080
dc.descriptionNorris, D.A., Capin, L., Muglia, J.J., Enhaced susceptibility of melanocytes of different immunologic effector mechanisms in vitro: Potential mechanisms for postinflammatory hypopigmentation and vitiligo (1998) Pigment Cell Research, pp. 113-123
dc.descriptionFishman, P., Vitiligo antibodies are effective against melanoma (1993) Cancer, 72, pp. 2365-2369
dc.descriptionNaughton, G.K., Reggiardo, M.D., Bystryn, J.-C., Correlation between vitiligo antibodies and extent of dispigmentation in vitiligo (1986) J Am Acad Dermatol, 15, pp. 978-981
dc.descriptionZiegler, I., Production of pterdines during hematopoiesis and T-lymphocyte proliferation-potencial participation in the control of cytokine signal transmission (1998) Medicinal Research Reviews, 10, pp. 95-114
dc.descriptionBleehen, S.S., Despigmentation of skin with 4-isopropyl-catechol, mercaptoamines, and other compounds (1968) J Invest Dermatol, 50, pp. 103-117
dc.descriptionRiley, P.A., Mechanisms of pigment cell toxicity produced by hydroxyanisole (1970) J Pathol, 101, pp. 163-169
dc.descriptionLerner, A.B., On the etiology of vitiligo and gray hair (1971) Am J Med, 51, pp. 141-147
dc.descriptionReedy, M.V., Regulation of melanoblast migration and differentiation (1998) The Pigmentary System Physiology and Pathophysiology, pp. 75-95. , New York: Oxford University Press
dc.descriptionBarnes, L., Vitiligo and the Vogt-Koyanagi- Harada syndrome (1988) Dermatol Clin, 6, pp. 229-239
dc.descriptionNellhaus, G., Acquired unilateral vitiligo and poliosis of the head and subacute encephalitis with partial recovery (1970) Neurology, 20, pp. 961-974
dc.descriptionSchallreuter, K.U., Vitiligo and other disease: Coexistence or true association? Hamburg study on 321 patients (1994) Dermatology, 188, pp. 269-275
dc.descriptionDavis, M.D., (1992) 7-Tetrahydrobiopterin, a Natural Occurring Analogucof Tetrahydrobiopterin is a Cofator for, and a Potencial Inhibtor of the Aromatic Amino Acid Hydrolases, 89, pp. 10108-10113. , National Academy of Sciences, USA
dc.descriptionLei, X.-D., Expression of 4a- carbinolamine dehydratasein human epidermal keratinocytes (1997) Bichem Biophys Res Commun, 238, pp. 556-559
dc.descriptionCormane, R.H., Siddiqui, A.H., Schutgens, R.B.H., Phenylalanine and UVA light for the treatment of vitiligo (1985) Arch Dermatol Res, 277, pp. 126-130
dc.descriptionHand, S.K., Lee, H.J., Segmental vitiligo: Clinical findings in 208 patients (1996) J Am Acad Dermatol, 36, pp. 671-674
dc.descriptionJaisankar, T.J., Vitiligo in children (1993) Int J Dermatol, 31, pp. 621-623
dc.descriptionPal, S.K., Thyroid function in vitiligo (1980) Clinica Chimica Acta, 106, pp. 331-332
dc.descriptionGrimes, P.E., Autoantibodies and their clinical significance in a black vitiligo population (1983) Arch Dermatol, 119, pp. 300-303
dc.descriptionKorkij, W., Tissue-specific autoantibodies and autoimmune disorders in vitiligo and alopecia areata: A retrospective study (1984) J Cutan Pathol, 11, pp. 522-530
dc.descriptionLerner, A.B., Vitiligo (1959) J Invest Dermatol, 32, pp. 285-310
dc.descriptionLe Poole, I.C., Presence or absence of melanocytes in vitiligo lesions: An immunohistochemical investigation (1993) J Invest Dermatol, 100, pp. 816-822
dc.descriptionHu, F., In vitro studies of vitiligo (1959) J Invest Dermatol, 33, pp. 267-280
dc.descriptionFalabella, R., Idiopathic gruttate hypomelanosis (1988) Dermatol Clin, 6, pp. 241-247
dc.descriptionStaricco, R.G., Amelanotic melanocytes in the outer sherth of the hair follicles (1959) J Invest Dermatol, 33, pp. 295-297
dc.descriptionCui, J., Shen, L.Y., Wang, G.C., Role of hair folicles in the repigmentation of vitiligo (1991) J Invest Dermatol, 97, pp. 410-416
dc.descriptionKandil, E., Treatment of localized vitiligo with intradermal injection of triamcinolone acetonide (1970) Dermatologica, 140, pp. 195-206
dc.descriptionKumari, J., Vitiligo treated with topical clobetasol propionate (1984) Arch Dermatol, 120, pp. 631-635
dc.descriptionKoga, M., Vitiligo: A new classification and therapy Br J Dermatol, 97, pp. 255-261
dc.descriptionVisitha, L.K., Singh, G., Vitiligo and intralesional steroids (1979) Indian J Med Res, 69, pp. 308-311
dc.descriptionHann, S.K., Systemic steroids suppress antimelanocyte antibodies in vitiligo (1997) J Cutan Med Surg, 1, pp. 193-195
dc.descriptionPasricha, J.S., Oral Mini-pulse therapy with betamethasone in vitiligo patients having extensive or fast-spreading disease (1993) Int J Dermatol, 31, pp. 753-757
dc.descriptionKim, S.M., The efficacy of low-dose oral corticosteroids in the treatment of vitiligo patients (1999) Int J Dermatol, 38, pp. 546-550
dc.descriptionParrish, J.A., Fitzpatrick, T., Photochemotherapy of vitiligo. Use of orally administered psoralens and a high-intensity long-wave ultraviolet light system (1976) Arch Dermatol, 112 (11), pp. 1531-1534
dc.descriptionGrimes, P.E., Minus, H.R., Determination of optimal topical photochemotherapy for vitiligo (1982) J Am Acad Dermatol, 7 (6), pp. 771-778
dc.descriptionHalder, R.M., Grimes, P.E., Childhood vitiligo (1987) J Am Acad Dermatol, 16 (5 PART 1), pp. 948-954
dc.descriptionOrtonne, J.P., Mosher, D.V., (1993) Vitiligo and Other Hypomelanoses, , Plenum Publisshing Co., New York
dc.descriptionSkouge, J.W., Morison, W.L., Autografting and PUVA. A combination therapy for vitiligo (1992) J Dermatol Surg Oncol, 18 (5), pp. 357-360
dc.descriptionBleehen, S.S., The treatament of vitiligo with topical corticosteroids. Light and electron-microscopic studies (1996) Br J Dermatol, 94 (SUPPL. 12), pp. 43-50
dc.descriptionFalabella, R., Arrunátegui, A., Barona, M.I., Alzate, A., The mini-grafting tet for vitiligo: Detection of stable lesions for melanocyte transplatation (1995) J Am Acad Dermatol, 32, pp. 228-232
dc.descriptionMoellman, G., Klein-Angerer, S., Scollay, D., Nordlund, J.J., Lerner, A., Extracelular granular material and degeneration of keratinocytes in normally pigmented epidermis of patientes with vitiligo (1982) J Invest Dermatol, 79, pp. 321-330
dc.descriptionHalder, R., Pham, H., Breadon, J., Johnson, B., Micropigmentation for the treatment of vitiligo (1989) J Dermatol Surg Oncol, 15, pp. 1092-1098
dc.descriptionSchallreuter, K.U., Pittelkow, M.R., Low catalase levels in the epidermis of patients with vitiligo (1991) J Invest Dermatol, 97, pp. 1081-1085
dc.descriptionSchallreuter, K.U., Wood, J.M., Lemke, K.R., Levenig, C., Treatament of vitiligo with a topical application of pseudocatalase and calcium in combination with short term UVB exposure: A case on 33 patients (1995) Dermatology, 190, pp. 223-229
dc.descriptionMaresca, V., Rocella, M., Camera, E., Increased sensitivity to peroxidative agents as a possible pathogenic factor of melanocyte damage in vitiligo (1997) J Invest Dermatol, 109, pp. 310-313
dc.descriptionPatipa, M., Eyelid tattooing (1987) Deramtol Clin, 5, pp. 335-348
dc.descriptionCalanchini-Postizzi, E., Frenk, E., Long-term actinic damage in sun-exposed vitiligo and mormally pigmented skin (1987) Dermatologica, 174, pp. 266-271
dc.descriptionAbdel-Malek, A., Swope, V., Dixon, K., A possible unique mechanism for UVB induced hyperpigmentation (1993) International Pigment Cell Conference, p. 5. , London, 26-30 September
dc.descriptionNordlund, J.J., Melagenina and vitiligo (Reply) (1992) Dermatology, 184 (2), pp. 154-155
dc.descriptionMorliere, P., Honigsmann, H., Averbeck, D., Phototherapeutic, photobiologic and photosensitizing properties of khellin (1998) J Invest Dermatol, 90, pp. 720-724
dc.descriptionAntoniou, C., Schulpis, H., Michas, T., Vitiligo therapy with oral and topical phenylalanine with UVA exposure (1998) Int J Dermatol, 184 (2), pp. 153-155
dc.descriptionGreiner, D., Ochsendorf, F.R., Milbradt, R., Vitiligo-therapie mit phenylalanin/UVA. Katammnestiche untersuchungen nach funf jahren (1994) Hautarzt, 45, pp. 460-463
dc.descriptionMontes, L.F., Folic acid and vitamin B 12 in vitiligo: A nutritional approach (1992) Cutis, 50, pp. 39-42
dc.descriptionMonk, B., Topical flurouracil in vitiligo (1985) Arch Dermatol, 121, pp. 25-26
dc.descriptionPicardo, M., Passi, S., Morrone, A., Grandineti, M., Di Carlo, A., Ippolito, F., Antioxidant status in the blood of patients with active vitiligo (1994) Pigment Cell Research, 7, pp. 110-115
dc.descriptionNakamura, T., Pinnell, S.R., Darr, D., Vitamin C abrogates the deleterious effects of UVB radiation on cutaneous immunity by a mechanism that does not depend on THF-alfa (1997) J Invest Dermatol, 109, pp. 20-24
dc.descriptionPasricha, J.S., Khera, V., Effect of prolonged treatament with levamisole on vitiligo with limited and low-spreading disease (1994) Int J Dermatol, 33 (8), pp. 584-587
dc.descriptionGokhale, B.B., Cyclophosphamide and vitiligo (1979) Int J Dermatol, 18, p. 92
dc.descriptionGrimes, P.E., Soriane, T., Dytoc, M.T., Topical tacrolimus for repigmentation of vitiligo (2002) J Am Acad Dermatol, 47 (5), pp. 789-791
dc.descriptionTanghetti, E.A., Tacrolimus ointrent 0,1% produces repigmentation in patients with vitiligo: Results of a prospective patients series (2003) Cutis (Cutis), 71 (2), pp. 158-162
dc.languagept
dc.languageen
dc.publisher
dc.relationAnais Brasileiros de Dermatologia
dc.rightsaberto
dc.sourceScopus
dc.titleVitiligo [vitiligo]
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución